利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

174 条记录 (耗时 0.044 秒)

    Microfluidic device having stable static gradient for analyzing chemotaxis
    14.
    发明授权
    Microfluidic device having stable static gradient for analyzing chemotaxis 有权
    具有稳定静态梯度分析趋化性的微流体装置

    公开(公告)号：US08377685B2

    公开(公告)日：2013-02-19

    申请号：US12267524

    申请日：2008-11-07

    申请人： Ivar Meyvantsson ,  John Majer ,  Steven Hayes

    发明人： Ivar Meyvantsson ,  John Majer ,  Steven Hayes

    IPC分类号： G01N33/53 ,  C12Q1/24 ,  C12Q1/20 ,  C12M1/00 ,  C12M3/00 ,  C12M1/34

    CPC分类号： B01F13/0059 ,  B01F15/0404 ,  B01L3/5027 ,  B01L3/502723 ,  B01L3/50273 ,  B01L3/502738 ,  B01L2200/14 ,  B01L2300/0816 ,  B01L2300/088 ,  B01L2300/14 ,  B01L2400/0472

    摘要： A microfluidic method and device for testing and analyzing chemotaxis by providing a stable, static fluid gradient. The device includes a sink reservoir for receiving biological cellular material and a source reservoir for receiving a chemoattractant. The biological cellular material migrates through a low fluid volume microfluidic gradient channel located between the source and sink reservoirs. The fluid in the gradient channel is static and stable due to a high fluid volume closed circuit bypass microfluidic channel also in fluid communication with the source and sink reservoirs, whereby the bypass channel relieves any pressure differential imparted across the gradient channel.

    摘要翻译： 通过提供稳定的静态流体梯度来测试和分析趋化性的微流体方法和装置。 该装置包括用于接收生物细胞材料的汇水槽和用于接收化学吸收剂的源储存器。 生物细胞物质通过位于源和水槽之间的低流体体积微流体梯度通道迁移。 梯度通道中的流体是静态和稳定的，这是由于高流体体积闭合回路旁路微流体通道，其也与源和汇储槽流体连通，由此旁路通道减轻跨过梯度通道施加的任何压差。

    Method for screening for bacterial conjunctivitis
    16.
    发明授权
    Method for screening for bacterial conjunctivitis 有权
    筛选细菌性结膜炎的方法

    公开(公告)号：US07727513B2

    公开(公告)日：2010-06-01

    申请号：US11303001

    申请日：2005-12-15

    申请人： John Gavin MacDonald ,  Stephanie M. Martin ,  Jason Lye

    发明人： John Gavin MacDonald ,  Stephanie M. Martin ,  Jason Lye

    IPC分类号： A61K49/00 ,  C12Q1/20 ,  C12Q1/22 ,  C12Q1/04

    CPC分类号： C12Q1/04 ,  C12Q1/14

    摘要： A method for rapidly detecting infectious conjunctivitis in a host is provided. The method includes contacting an ocular test sample with a chromogen (e.g., Reichardt's dye) that exhibits a color change in the presence of a microbe. The present inventors have discovered that the extent of the color change may vary depending on whether the microbe is a bacteria or virus. Without intending to be limited by theory, the present inventors believe that the chromogen interacts with the peptidoglycan-based cell wall structure of bacteria to induce a color change that is even more apparent at infectious levels. It is believed that this interaction occurs to a much greater extent in bacteria than in viruses. Accordingly, although the chromogen may still undergo a color change in the presence of the viruses, it is typically to a much lesser extent. In this manner, the degree of color change of the chromogen may be used in the present invention as a mechanism for differentiating between viral and bacterial conjunctivitis.

    摘要翻译： 提供了一种快速检测宿主感染性结膜炎的方法。 该方法包括使眼睛测试样品与在微生物存在下显示颜色变化的色原体（例如，Reichardt's染料）接触。 本发明人已经发现，颜色变化的程度可以根据微生物是细菌还是病毒而变化。 不期望受理论的限制，本发明人相信色原体与细菌的基于聚肽聚糖的细胞壁结构相互作用以诱导在感染水平上更加明显的颜色变化。 相信这种相互作用在细菌中比在病毒中更大程度地发生。 因此，虽然染色体在病毒存在的情况下仍可能发生颜色变化，但通常其程度要小得多。 以这种方式，在本发明中可以使用色原体的颜色变化程度作为区分病毒和细菌性结膜炎的机制。

    Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents
    18.
    发明授权
    Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents 有权
    用于检测病原体，微生物污染物和/或成分的模块化复合多批筛选方案

    公开(公告)号：US07534584B2

    公开(公告)日：2009-05-19

    申请号：US11199871

    申请日：2005-08-08

    申请人： Mansour Samadpour

    发明人： Mansour Samadpour

    IPC分类号： C12Q1/24 ,  C12Q1/04 ,  C12Q1/06 ,  C12Q1/08 ,  C12Q1/10 ,  C12Q1/14 ,  C12Q1/20

    CPC分类号： C12Q1/10 ,  C12Q1/04 ,  C12Q1/18 ,  C12Q1/24 ,  G01N1/28 ,  Y10S435/849

    摘要： Particular aspects provide a method of sampling, testing and validating test lots (e.g., single-unit production lots), comprising: assembling a plurality of product portions from each of a plurality of test lots and combining the collected product portions to provide a corresponding set of test lot samples (wherein each test lot sample is attributed to a particular corresponding test lot); enriching the set of test lot samples; removing equal portions of each enriched sample, and combining the removed portions to provide a modular composite sample; and testing of the modular composite sample for the target agent/organism, wherein where such testing is positive, individual test lots may nonetheless yet be validated by further testing of a respective enriched test lot sample and obtaining a negative test result. The methods have broad utility for monitoring all sort of test lots (e.g., environmental lots, production lots, pharmaceutical lots, etc.) and for efficiently affecting informed, targeted remedial measures.

    摘要翻译： 特定方面提供了一种采样，测试和验证测试批（例如单一单位生产批）的方法，包括：从多个测试批中的每一个组装多个产品部分并组合收集的产品部分以提供相应的组 的测试批次样品（其中每个测试批样品归因于特定的相应测试批次）; 丰富了一批试样批次; 除去每个富集的样品的相等部分，并组合去除的部分以提供模块化的复合样品; 以及用于目标试剂/生物的模块化复合材料样品的测试，其中在这种测试为阳性的情况下，单个测试批可以通过进一步测试相应的富集测试批样品并获得阴性测试结果来验证。 这些方法具有广泛的用途，用于监测所有类型的测试批（例如环境批次，生产批次，药品批次等），并有效地影响知情的，有针对性的补救措施。

    Hif Modulating Compounds and Methods of Use Thereof
    19.
    发明申请
    Hif Modulating Compounds and Methods of Use Thereof 审中-公开
    Hif调节化合物及其使用方法

    公开(公告)号：US20080213404A1

    公开(公告)日：2008-09-04

    申请号：US11883692

    申请日：2006-02-03

    申请人： Randall S. Johnson ,  Carole Peyssonnaux ,  Victor Nizet ,  Emmanuel Theodorakis

    发明人： Randall S. Johnson ,  Carole Peyssonnaux ,  Victor Nizet ,  Emmanuel Theodorakis

    IPC分类号： A61K36/00 ,  C12Q1/20

    CPC分类号： A61K31/00

    摘要： A method is provided for treating subjects, including humans, with infection or virulence by pathogens. The method involves administering an agent in amounts effective to eradicate or reduce infections and/or an inflammatory response caused by pathogens. Methods for identifying compounds useful as anti-infectives that decrease the immune resistance, virulence, or growth of microbes are also provided. More particularly, there are provided methods for identifying compounds which increase accumulation or stability or activity, or alternatively decrease the degradation of HIF-1a protein.

    摘要翻译： 提供了一种治疗受试者，包括人类受病原体感染或毒力的方法。 该方法包括以有效消除或减少由病原体引起的感染和/或炎症反应的量施用药剂。 还提供了用于鉴定可用作降低微生物的免疫抗性，毒力或生长的抗感染剂的化合物的方法。 更具体地，提供了用于鉴定增加积聚或稳定性或活性或者可选地降低HIF-1a蛋白质降解的化合物的方法。